AMN Healthcare Services (NYSE:AMN): Q2 Non-GAAP EPS of $0.77 beats by $0.06; GAAP EPS of $0.61 beats by $0.05.
Revenue of $535.18M (-4.1% Y/Y) beats by $9.12M.
Tuesday, August 6, 2019
Halozyme Therapeutics EPS beats by $0.05, misses on revenue
Halozyme Therapeutics (NASDAQ:HALO): Q2 GAAP EPS of -$0.10 beats by $0.05.
Revenue of $39.15M (+11.2% Y/Y) misses by $3.79M.
DuPont considers potential $20B sale of biosciences unit
DuPont (DD +3.8%) is considering unloading its nutrition and biosciences division, and is working with advisers to evaluate options that could include selling or spinning off the business, Bloomberg reports.
The division, which makes food additives and ingredients, could be worth at least $20B as a stand-alone entity, based on the trading multiples of rivals, according to the report.
Logical partners for such a deal are said to include International Flavors & Fragrances (NYSE:IFF), Kerry Group (OTCPK:KRYAY), Givaudan (OTCPK:GVDBF) and Royal DSM.
Zogenix EPS misses by $0.11, misses on revenue
Zogenix (NASDAQ:ZGNX): Q2 GAAP EPS of -$0.89 misses by $0.11.
Revenue of $1.07M misses by $3.04M.
Cash, cash equivalents, and marketable securities of $463M
Flexion Therapeutics EPS beats by $0.09, beats on revenue
Flexion Therapeutics (NASDAQ:FLXN): Q2 GAAP EPS of -$0.96 beats by $0.09.
Revenue of $16.95M (+347.2% Y/Y) beats by $1.99M.
PTC Therapeutics Q2 Translarna sales up 21%
PTC Therapeutics (NASDAQ:PTCT) Q2 results: Revenues: $85.5M (+24%); Translarna sales: $57.8M (+21%).
Net loss: ($41.8M).
U.S. marketing application for risdiplam for SMA Types 1,2&3 to be filed later this year followed by an application in Europe in H1 2020.
2019 guidance: DMD product sales: $285M – 305M (unch).
Previously: PTC Therapeutics EPS misses by $0.17, beats on revenue (Aug. 6)
Weight Watchers EPS beats by $0.13, misses on revenue
Weight Watchers (NASDAQ:WW): Q2 GAAP EPS of $0.78 beats by $0.13.
Revenue of $369M (-9.9% Y/Y) misses by $7.11M.
Shares +9.47%.
Subscribe to:
Posts (Atom)